相关实验视频
Updated: Jul 4, 2026

11:28
Analytical Techniques for Assaying Nitric Oxide Bioactivity
Published on: June 18, 2012
西尔德纳菲尔酸盐 (Viagra) 结合酸盐对心脏的影响
F Ishikura1, S Beppu, T Hamada
1School of Allied Health Sciences, Osaka University, Faculty of Medicine, Osaka, Japan.
Circulation
|November 15, 2000
概括
西尔德纳菲尔酸盐 (Viagra) 扩大正常的冠状动脉,但当与酸盐相结合时,可以导致血压和冠状动脉血流的危险下降,特别是在狭窄的血管中.
科学领域:
- 心血管药理学心血管药理学
- 药理动力学是什么 药理动力学
- 血液动力学 血液动力学
背景情况:
- 西尔德纳菲尔酸盐 (Viagra) 用于治疗勃起功能障碍.
- 与酸甘的同时使用导致显著的低血压.
- 锡尔德纳菲尔酸盐和酸盐对冠状动力学的相互作用需要研究.
研究的目的:
- 为了研究西尔代纳菲尔酸盐对冠状动脉血流的影响.
- 评估西尔代纳菲尔酸盐和酸盐对全身血压和冠状动力学的联合作用.
主要方法:
- 血液动力学参数 (全身血压,肺动脉压,冠状动脉血流) 在健康的雄性比格尔犬中进行测量.
- 施用了西尔德纳菲尔酸盐,随后对冠状动脉血流进行了评估.
- 在西尔代纳菲尔酸盐被注射之前和之后,研究了异索二酸盐的急性作用.
主要成果:
- 西尔德纳菲尔酸盐增加了左前下垂冠状动脉的血液流动.
- 系统血压,肺动脉压或环动脉流量没有显著变化.
- 酸盐和西尔德纳菲尔酸盐的联合使用导致系统血压和冠状动脉血流在狭窄的血管中显著更大,更长时间的下降.
结论:
- 西尔德纳菲尔酸盐对正常的冠状动脉表现出血管扩张作用.
- 与酸盐相结合的西尔德纳菲尔酸盐可以导致显著和长时间的低血压和降低冠状动脉血流,特别是在动脉缩的关键动脉.
相关概念视频
Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

